TABLE 2.

Resistance profiles of diverse HIV fusion inhibitors^a

Pseudovirus	LP-52		T20		LP-80		LP-83		LP-19
	EC50 (nM)	FC	EC50 (nM)	FC	EC50 (nM)	FC	EC50 (nM)	FC	EC50 (nM)	FC
SIVmac239
WT	0.09 ± 0.01	1	394.55 ± 22.56	1	0.03 ± 0.001	1	0.002 ± 0.000	1	0.38 ± 0.03	1
F346L	0.08 ± 0.03	0.94	400.58 ± 30.16	1.02	0.03 ± 0.004	1.09	0.002 ± 0.000	1	0.38 ± 0.02	0.99
V562A	27.59 ± 3.31	324.6	23832.66 ± 1590.59	60.4	1.83 ± 0.43	70.19	0.025 ± 0.002	12.67	0.33 ± 0.03	0.86
V562M	2.69 ± 0.41	31.65	3188.33 ± 775.16	8.08	0.38 ± 0.05	14.46	0.013 ± 0.001	6.5	0.25 ± 0.01	0.67
E657G	0.44 ± 0.2	5.12	811.77 ± 228.22	2.06	0.17 ± 0.01	6.5	0.006 ± 0.001	3.17	1.35 ± 0.26	3.55
S760G	0.07 ± 0.02	0.76	339.27 ± 74.99	0.86	0.03 ± 0.01	1.1	0.002 ± 0.001	0.83	0.36 ± 0.03	0.94
V562A/E657G	403.5 ± 76.27	4747	21548.56 ± 2143.45	54.62	108.78 ± 6.61	4184	0.696 ± 0.140	348	1.24 ± 0.22	3.27
V562M/E657G	34.12 ± 14.1	401.4	5344.44 ± 872.17	13.55	3.19 ± 0.49	122.5	0.09 ± 0.004	45.17	0.73 ± 0.05	1.92
V562A/S760G	20.93 ± 5.49	246.2	12122.89 ± 2895.06	30.73	1.03 ± 0.09	39.65	0.031 ± 0.006	15.33	0.36 ± 0.03	0.95
V562M/S760G	3.31 ± 0.89	38.94	2795.22 ± 370.75	7.08	0.31 ± 0.05	11.76	0.014 ± 0.004	6.83	0.21 ± 0.01	0.56
E657G/S760G	0.38 ± 0.17	4.47	899.03 ± 92.97	2.28	0.13 ± 0.03	4.82	0.006 ± 0.001	3	1.06 ± 0.09	2.78
HIV-1 NL4-3
WT	0.01 ± 0.002	1	103.18 ± 2.49	1	0.004 ± 0.001	1	0.002 ± 0.000	1	0.14 ± 0.02	1
V547A	0.27 ± 0.03	42.26	1577.78 ± 204.37	15.29	0.25 ± 0.06	62	0.016 ± 0.001	8	0.16 ± 0.003	1.16
V547M	0.15 ± 0.02	23.16	537.26 ± 58.61	5.21	0.12 ± 0.02	31	0.008 ± 0.001	4	0.21 ± 0.01	1.49
E646G	0.01 ± 0.002	1.84	125.97 ± 9.46	1.22	0.01 ± 0.004	3	0.001 ± 0.000	0.5	0.17 ± 0.02	1.24
V547A/E646G	0.71 ± 0.15	111.6	1519.33 ± 164.57	14.73	0.67 ± 0.1	167.8	0.043 ± 0.016	21.5	0.17 ± 0.03	1.23
V547M/E646G	0.39 ± 0.04	62.11	660 ± 56.7	6.4	0.26 ± 0.08	65.75	0.011 ± 0.004	5.5	0.2 ± 0.06	1.44

^aData were derived from three independent experiments and express as means ± standard deviations; FC, fold change; EC₅₀, 50% effective concentration.